Articles By Rob Wright, Chief Editor 2011-2021

-
Are We On The Precipice Of Unprecedented Collaboration In Biopharma?1/28/2021
The recent announcement of Sanofi agreeing to help produce Pfizer's COVID-19 vaccine could represent biopharma's entry into a period of unprecedented collaboration.
-
Let's Talk About JPM 20211/19/2021
Rob Wright, chief editor of Life Science Leader, shares thoughts on attending the 39th Annual J.P. Morgan Healthcare Conference (JPM) which was 100% virtual this year.
-
What Went Right In 2020? My Top 5 List1/5/2021
Life Science Leader's Rob Wright reviews five things that went right in 2020.
-
Frank Gupton – Revolutionizing Pharma Manufacturing From The Outside In1/4/2021
“I’ve gotten more press during the last six and a half months than in my 68 years on this earth,” jokes Frank Gupton, Ph.D., a professor at Virginia Commonwealth University who has been involved in some key recent developments in pharma manufacturing.
-
How A First-Time Pharma CEO Faces Hypergrowth1/4/2021
Jeffrey Nau, Ph.D., discusses the career path that led him to becoming president and CEO of Oyster Point Pharma, a publicly traded biopharma now valued at more than $550 million and on the brink of commercial launch.
-
New Year, New President, New Outlook1/4/2021
New Year’s is not just a time of celebration, but a point at which we step out of the day-to-day to reflect on how we did — and resolve to do better.
-
What Do 10 Biopharma Finance Experts Expect for 2021?12/1/2020
We invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations.
-
The Future Of Biopharma Manufacturing Has Never Been More Critical12/1/2020
Here’s what six biopharmaceutical manufacturing executives have to say on emerging manufacturing innovations, key trends to pay attention to in 2021 (and beyond), and so much more.
-
What's The Annual Outlook For Life Sciences In 2021?12/1/2020
As we’ve done previously, this year we posed many questions to lots of executives across a variety of life science industry disciplines, and here you will gain perspectives on what to expect on biosimilars to outsourcing, and everything in between.